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Myeloid-derived suppressor cells (MDSCs) play a major role in cancer. MDSC expansion is closely associ-
ated with tumor progression, but molecular mechanisms of this expansion remain poorly understood. In
this issue of Cancer Cell, Strauss and colleagues describe the roles of the nuclear receptor ROR1C in the
regulation of MDSC differentiation and expansion.The accumulation of non-lymphoid sup-
pressive cells in cancer was first reported
in the late 1970s, but these cells had at-
tracted very little attention until 15 years
ago, when their potential contribution
to tumor progression became apparent.
These cells have been named myeloid-
derived suppressor cells (MDSCs) to
reflect their origin and major functional
feature—the ability to suppress T cell acti-
vation and function. In addition, the role of
MDSCs in promoting tumor growth by
supporting angiogenesis, tumor cell sur-
vival, metastases, and formation of pre-
metastatic niches has been established
(Condamine et al., 2015). Recent studies
have provided ample evidence of the clin-
ical relevance of MDSCs (Messmer et al.,
2015). MDSCs are phenotypically distinct
from terminally differentiated dendritic
cells (DCs) and macrophages and repre-
sent a heterogeneouspopulation of imma-
ture myeloid cells that include cells with
granulocytic and monocytic morphology
and phenotype. MDSCs are now divided
into two major populations: polymor-
phonuclear-MDSCs (PMN-MDSCs) and
monocytic-MDSCs (M-MDSCs) (Mova-
hedi et al., 2008; Youn et al., 2008). In a
majority of cancer types, PMN-MDSCs,which have a phenotype and morphology
similar to those of neutrophils, represent
70%–80% of the total MDSC popula-
tion. However, in contrast to neutrophils,
PMN-MDSCs suppress T cell functions
and have a distinct gene expression pro-
file and a number of distinct functional
characteristics. M-MDSCs share their
phenotype and morphology with normal
monocytes. In contrast to spleen mono-
cytes in naive mice and blood monocytes
in healthy individuals, M-MDSCs have a
potent ability to suppress T cell functions,
which ismediated by arginase-1, nitric ox-
ide (NO), and different soluble factors
(Gabrilovich et al., 2012). MDSCs arise
from a common myeloid progenitor.
Their development is supported by the
same growth factors that are responsible
for the normal myelopoiesis: granulo-
cyte macrophage colony-stimulating fac-
tor (GM-CSF), granulocyte colony-stimu-
lating factor (G-CSF), and macrophage
colony-stimulating factor (M-CSF) (Bayne
et al., 2012; Dolcetti et al., 2010; Kowanetz
et al., 2010). However, simple expansion
of myeloid cells is not sufficient to
generate bona fide MDSCs. MDSCs exist
in the state of pathological activation,
which is the result of persistent stimulationof themyeloid compartmentwith relatively
low strength signals coming from tumors
or sites of chronic inflammation. Myeloid
cells generated under these conditions
are unable to effectively differentiate into
mature myeloid cells, are poorly phago-
cytic, and produce high levels of reactive
oxygen species, myeloperoxidase, nitric
oxide, andmostly anti-inflammatory cyto-
kines. As a result, these cells acquire
potent immune suppressive potential.
The molecular mechanisms that govern
such pathological expansion are sub-
jects of intense investigations. Different
factors were implicated in this process.
They include signal transducer and acti-
vator of transcription 3 (STAT3) and 5,
NF-kB, paired immunoglobulin-like re-
ceptor B, CCAAT/enhancer binding pro-
tein b (C/EBPb), interferon regulatory fac-
tor 8 (IRF8), retinoblastoma protein (Rb),
and other. In this issue of Cancer Cell
Strauss et al. (2015) identified novelmech-
anisms that involved RORC1.
RORC1and its splicevariantRORC2are
master regulators of IL-17A gene tran-
scription. Authors were interested in
RORC1 because they found increased
expression of IL-17A by PMN-MDSCs in
















Figure 1. RORC1 Involvement in Myeloid Lineage Differentiation
Brown shows the general pathway of differentiation of neutrophils and mononuclear cells in healthy indi-
viduals. Hematopoietic stem cells (HSC) differentiate into common myeloid progenitors (CMP), then into
granulocytesmacrophage progenitors (GMP), which give rise tomature neutrophils via sequential steps of
differentiation involving myeloblasts (MB), promyelocytes (PM), myelocytes (MC), metamyelocytes (MM),
and band forms (BF). Differentiation of macrophages (MF) and DCs involve macrophage/dendritic cell
progenitors (MDP), DC progenitors (CDP), pre-cDCs, as well as several types of monocytes. In cancer
(blue), tumor-derived factors regulate various molecular pathways, including upregulation of RORC1,
which affect all steps of granulocytic and monocytic cell differentiation. RORC1 promotes the accumula-
tion of immature pathologically activated PMN-MDSC neutrophils for the expense of mature PMN. M-
MDSCs differentiate to TAM in the tumor site. RORC1 promotes polarization toward the M2 phenotype
of TAM.
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MDSCs and macrophages lacked expres-
sion of IL-17A. The majority of blood and
spleen PMN-MDSCs expressed RORC1.
Tumor-bearing mice deficient for RORC1
showed a significant expansion of the
granulocytic compartment, which was
associated with a progressive contraction
of the erythroid colonies and signs
of dysmegakaryopoiesis. Data indicated
that Rorc/ tumor-bearing mice effec-
tively supported emergency hematopoie-
sis while displaying a defective induction
of MDSCs.
To investigate in vivo relevance of
RORC1-expressing myeloid cells, Strauss
et al. (2015) transplantedRORC1-deficient
bone marrow (BM) cells into lethally irradi-
ated wild-type (WT) recipient mice. Tumor
growth and metastasis were significantly
reduced in these mice, and this was
accompanied by a dramatic reduction of
splenic MDSCs. These results implied
that RORC1 promoted the expansion of
splenic MDSCs. These conclusions were
supported by the increase in the metasta-
tic burden and the presence of splenic
M-MDSCs and PMN-MDSCs in tumor-148 Cancer Cell 28, August 10, 2015 ª2015 Ebearing mice treated with ROR1C agonist
SR1078.
As compared to the recipients of WT
BM, Rorc/ BM chimeras have a sub-
stantially higher number of hematopoietic
stem and common myeloid progenitors
but a decreased number of granulocyte/
macrophage progenitors, suggesting a
possible block in differentiation of early
hematopoietic progenitors. In the pres-
ence of tumor-conditioned medium or in
response to GM-CSF, BM progenitors
from Rorc/ mice failed to differentiate
to macrophages, displaying increased
differentiation into granulocytes, while
treatment with G-CSF resulted in reduced
granulocytes production. These results
suggested a key role of RORC1 in the
myelopoietic activity of G- and GM-CSF.
In vitro-generated Rorc/ myeloid cells
had a higher level of apoptosis than
their WT counterparts, suggesting that
RORC1 can be involved in regulation of
the survival of these cells.
In an attempt to identify the mecha-
nisms of the effect of ROR1C on myelo-
poiesis, Strauss et al. (2015) studied
C/EBPb, a major positive regulator oflsevier Inc.G-CSF- and GM-CSF-driven ‘‘emer-
gency’’ myelopoiesis, and C/EBPa, a
major regulator of ‘‘steady state’’
granulopoiesis. A modest but significant
decrease of expression of PU.1, C/
EBPb, and C/EBPa was found in the
spleen and BM of Rorc/ > WT tumor-
bearing mice, which paralleled the
decrease of C/EBPb proteins in splenic
PMN-MDSCs and M-MDSCs. The BM
and spleen from Rorc/ > WT tumor-
bearing mice had increased mRNA levels
of the suppressor of cytokine signaling-3
(Socs3), which regulates STAT3 activity,
and the transcriptional co-regulator B
cell leukemia/lymphoma 3 (Bcl3), both
potent inhibitors of G-CSF-driven granu-
lopoiesis. Strauss et al. (2015) observed
a decreased number of IRF8-expressing
macrophages. RORC1-deficient macro-
phages displayed enhanced expression
of M1 and decreased expression of M2
genes, suggesting that RORC1 may act
as a negative regulator of M1 and a pro-
moter of M2 polarization. A decreased
number of tumor-associated macro-
phages (TAM) from Rorc/ > WT mice
correlated with increased PMN-MDSC
infiltration, suggesting that ROR1C path-
ways lead to terminal differentiation and
M2-polarization of TAM and hamper
neutrophil accumulation in tumors. To
test this assumption, tumor-bearing WT
mice were treated with CSFR1 antibody,
which significantly depleted TAM.
Macrophage depletion was paralleled
by the inhibition of immature RORC1+
M-MDSCs and PMN-MDSCs and
increased tumor infiltration of mature
neutrophils. Treatment of mice with M-
CSF antibody resulted in a similar in-
crease of mature neutrophils. Adminis-
tration of CSFR1 antibody led to reduced
monocyte/macrophage precursors and
increased granulocyte progenitors, sup-
porting the role for reciprocal negative
regulation of monocytes/macrophages
and granulocytes in cancer inflammation.
Treatment with G-CSF antibody signifi-
cantly decreased RORC1 expression in
PMN-MDSCs and partially in M-MDSCs
and macrophages. This effect was signif-
icantly reduced in Rorc/ mice, sup-
porting the hypothesis that G-CSF may
work through RORC1.
Although the precise mechanism res-
ponsible for upregulation of ROR1C in
cancer needs to be elucidated, this
study provides exciting insight into
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lopoiesis by one of the members of the
nuclear receptor superfamily and sug-
gests that RORC1 could be a key driver
of the differentiation of MDSCs and TAM
(Figure 1).REFERENCES
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Molecular studies of intra-tumor heterogeneity (ITH) are revealing a large amount of DNA-based variation
in many individual tumors. In a recent publication by Yates and colleagues, the ITH of breast tumors was
examined and shown to have important implications for the development of resistant disease, metastasis,
and clinical sequencing efforts.Human breast cancer shows great
inter-tumor diversity in every feature that
one might examine, including histology,
response to therapy, and patient survival
times. At the same time, there is a long
history of evidence for significant intra-
tumor heterogeneity (ITH), which can itself
be manifested in histological differences,
cellular differences, and molecular differ-
ences. In fact, studies on ITH as assessed
at the DNA level have been documented
and studied for decades (Kallioniemi,
1988). The new study by Yates et al.
(2015) masterfully brings these ITH
DNA-based analyses into the 21st cen-
tury, providing an unprecedented look at
the sub-clonal composition of individual
breast tumors.
The first question addressed by the au-
thors was the amount of spatial ITH seen
within individual untreated primary tumors
through in-depth analysis of 12 patients
in which each tumor was sampled from
8 different locations. Each location wasthen subjected to deep sequencing using
360 and 454 gene panels. Two thirds
(i.e., 8 of 12) of the tumors showed clear
somatic mutation heterogeneity across
the different isolates from a single tumor;
2 of 12 showed copy number ITH; and 2
of 12 showed little genetic variation.
Thus, the majority of tumors showed mo-
lecular ITH, and, in most tumors, this was
spatially segregated. This characteriza-
tion of spatial ITH supports the findings
of others (Ding et al., 2010; Shah et al.,
2012), but with a larger number of breast
tumors. Finally, the authors highlight 4
of 12 cases in which the sub-clonal
mutations included important genes like
TP53, PIK3CA, and BRCA2. This finding
dictates the necessity to sequence at
high-depth in the clinical setting to
generate sensitive and specific sub-
clonal mutation calls.
The finding that oncogenic mutations
can be sub-clonal prompts the question
of whether these were present at diag-nosis or if they occurred later during tumor
evolution. Previous work in breast cancer
has shown that, within triple-negative
breast cancer (TNBC), TP53 mutations
are frequent and tend to be early events
(Ding et al., 2010; Shah et al., 2012). Yates
et al. (2015) extend this work using four
patients that presented with multi-focal
disease (i.e., two to five foci per patient).
In each case, foci were clearly genetically
related to the others within a patient but
also had many private mutations that
were present at high variant allele frac-
tions (VAF). The authors infer that individ-
ual foci must have arisen from a common
ancestor, and thus their spatial separation
was almost akin to local metastasis. Sec-
ond, each foci must have undergone
a ‘‘clonal sweep’’, evident by numerous
private mutations with high VAF. These
results are in line with those of other re-
searchers (Navin et al., 2011; Nik-Zainal
et al., 2012), supporting the concept of
‘‘clonal sweep’’ in breast cancer. Another, August 10, 2015 ª2015 Elsevier Inc. 149
